SCHEMBL5773404

SCHEMBL5773404

O=Cc1ccc([N+](=O)[O-])cc1I

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.58
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
PTPN1 P18031 1/20 0.46
TXNRD1 Q16881 1/20 0.46
TXNRD3 Q86VQ6 1/20 0.46
TXNRD2 Q9NNW7 1/20 0.46
ALDH1A1 P00352 6/20 0.45
TDP1 Q9NUW8 5/20 0.44
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
NAMPT P43490 1/20 0.43
XDH P47989 1/20 0.43
MAPT P10636 2/20 0.43
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 1/20 0.41
PTPRC P08575 1/20 0.41
S100A4 P26447 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3952327 0.85 ERN1 (0.62) ERN1LMNAHTTKMT2AMEN1
SCHEMBL2652355 0.82 ERN1 (0.69) ERN1LMNAHTTKMT2APTPN1
SCHEMBL203753 0.78 ERN1 (0.59) ERN1LMNAHTTKMT2AMEN1
SCHEMBL3030993 0.77 LMNA (0.56) LMNAHTTKMT2AMEN1TXNRD1
SCHEMBL6173137 0.77 ERN1 (0.58) ERN1LMNAHTTPTPN1TXNRD1
SCHEMBL2616938 0.77 ERN1 (0.58) ERN1HTTKMT2AMEN1PTPN1
SCHEMBL1591294 0.77 ERN1 (0.58) ERN1LMNAHTTKMT2AMEN1
SCHEMBL1858387 0.77 ALDH1A1 (0.62) ERN1LMNAHTTKMT2AMEN1
SCHEMBL918368 0.77 ERN1 (0.73) ERN1PTPN1TXNRD1TXNRD3TXNRD2
SCHEMBL1195413 0.77 HSD17B10 (0.62) ERN1KMT2AMEN1PTPN1TXNRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1112548-A Polyiodinated compounds, process for preparing them and diagnostic compositions GUERBET SA (FR) 1995-11-29 CN claimed
CN-115806568-A Method for constructing heteroatom substituted xanthene derivative through palladium-catalyzed cross coupling and application 华东师范大学 2023-03-17 CN disclosed
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed
CN-1112548-A Polyiodinated compounds, process for preparing them and diagnostic compositions GUERBET SA (FR) 1995-11-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT ERN1 1816/4885LMNA 861/4885HTT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.